3 Things About Cassava Sciences That Smart Investors Know

·5 min read
3 Things About Cassava Sciences That Smart Investors Know

Like other biotechs without any revenue, its value proposition to shareholders is contingent on the success of its clinical trials. The company's drug, simufilam, recently completed its phase 2 clinical trials, and the company plans to start phase 3 before the end of 2021. On July 29, Cassava reported a packet of data showing that simufilam improved cognition, slowed the progression of Alzheimer's disease, and elicited positive changes in a smattering of biomarkers.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting